责任编辑：小浪快报 截至9月30日，梅花生物股东户数6.67万，较上期增加13.10%；人均流通股42058股，较上期减少 13.09%。2025年1月-9月，梅花生物实现营业收入182.15亿元，同比减少2.49%；归母净利润30.25亿元， 同比增长51.61%。 分红方面，梅花生物A股上市后累计派现120.47亿元。近三年，累计派现40.75亿元。 机构持仓方面，截止2025年9月30日，梅花生物十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股9892.29万股，相比上期增加1833.66万股。国泰中证畜牧养殖ETF（159865）位居第七大 流通股东，持股4459.03万股，为新进股东。南方标普中国A股大盘红利低波50ETF联接A（008163）位 居第九大流通股东，持股3204.72万股，为新进股东。兴全合润混合A（163406）、兴全合宜混合A （163417）退出十大流通股东之列。 11月21日，梅花生物盘中下跌2.07%，截至13:56，报10.40元/股，成交3.07亿元，换手率1.04%，总市值 291.64亿元。 资金流向方面，主力资金净流出873.22万元，特大单买入16 ...

Core Insights - Meihua Biological reported a revenue of 18.215 billion yuan for the first three quarters of 2025, a year-on-year decrease of 2.49%, while net profit attributable to shareholders increased by 51.61% to 3.025 billion yuan [1] - The company achieved a significant increase in profitability in Q3 2025, with a single-quarter net profit of 1.257 billion yuan, up 141.06% year-on-year, despite a 1.71% decline in main business revenue [1] - Moody's confirmed the company's "Baa3" issuer rating and upgraded the outlook from "stable" to "positive," reflecting market recognition of the company's operational quality and credit status [1] Revenue and Profit Analysis - The slight decline in revenue was primarily due to falling market prices for products such as monosodium glutamate, threonine, lysine, and xanthan gum [1] - The company managed to achieve significant net profit growth through capacity release, cost advantages, and overseas acquisitions [1] - Increased sales volumes from subsidiaries producing monosodium glutamate and isoleucine contributed to the profit growth, alongside higher sales of lysine, feed valine, and starch by-products [1] Overseas Acquisition and Market Position - Meihua Biological made significant progress in overseas acquisitions, with an assessed value of 1.626 billion yuan for the combined equity of the acquired amino acid and HMO businesses [2] - The company expects to recognize approximately 780 million yuan in additional non-operating income in the 2025 fiscal year from this acquisition [2] - Successful completion of the acquisition of Japanese companies in July 2025 extended the product line and enhanced the company's international presence [2] Trade and Regulatory Response - In response to the EU's anti-dumping investigation on lysine, Meihua Biological effectively reduced the final tax rate from an initial 84.8% to 47.7%, improving price competitiveness [2] - The company demonstrated its expertise in handling international trade disputes through close communication with overseas clients [2] Project Development and R&D Investment - The Tongliao monosodium glutamate capacity upgrade project has reached full production, becoming one of the largest single monosodium glutamate production lines globally [2] - The Jilin lysine project is under construction and is expected to commence trial production in Q4 2025, contributing to the company's operational scale expansion [2] - Increased R&D investment has been made to advance the industrialization of synthetic biology technology, with a pilot research platform established in Jilin [3] Overall Performance and Future Outlook - Meihua Biological achieved significant net profit growth in the first three quarters of 2025 through various initiatives, including capacity release, cost optimization, overseas acquisitions, project development, and R&D investment [3] - The company is well-positioned to maintain a positive growth trajectory with the upcoming project launches and integration of acquisition activities [3]

Investment Rating - The investment rating for the company is "Outperform" [8] Core Views - The company's Q3 operational performance met expectations, with a revenue of 18.215 billion yuan, a year-on-year decrease of 2%, and a net profit attributable to shareholders of 3.025 billion yuan, a year-on-year increase of 52% [8] - The company is advancing its globalization strategy, having completed the consolidation of assets from a foreign acquisition, marking a new phase in its international expansion [8] - The forecast for the company's net profit attributable to shareholders for 2025 has been raised to 3.628 billion yuan due to the impact of merger gains, while forecasts for 2026 and 2027 have been adjusted downwards [8] Financial Data and Profit Forecast - Total revenue for 2025 is projected at 26.803 billion yuan, with a year-on-year growth rate of 6.9% [7] - The net profit attributable to shareholders for 2025 is estimated at 3.628 billion yuan, reflecting a year-on-year growth of 32.4% [7] - The company's gross margin is expected to be 19.7% in 2025, with a return on equity (ROE) of 22% [7] Market Data - The closing price of the company's stock is 11.28 yuan, with a market capitalization of 31.632 billion yuan [6] - The price-to-earnings (PE) ratio is projected to be 9 for 2025 [7]

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 12.70 [1][4]. Core Views - The company reported Q3 revenue of RMB 5.9 billion, a year-over-year decrease of 2% and a quarter-over-quarter decrease of 1%. However, the net profit attributable to the parent company was RMB 1.26 billion, showing a year-over-year increase of 141% and a quarter-over-quarter increase of 68% [1]. - The company’s net profit for the first three quarters of 2025 reached RMB 30.3 billion, a year-over-year increase of 52%, driven by the acquisition of an overseas company which contributed approximately RMB 7.8 billion to the profit [1][4]. - The report anticipates a recovery in the amino acid market, supported by increased penetration in the aquaculture sector and a favorable demand outlook due to reduced soybean meal usage [1][3]. Summary by Sections Financial Performance - For the first three quarters of 2025, the feed amino acids revenue was RMB 8.19 billion, down 2% year-over-year, while lysine sales increased despite price declines. The average prices for lysine and threonine were RMB 8.5/kg and RMB 10.0/kg, reflecting year-over-year decreases of 16% and 5% respectively [2]. - The overall gross margin improved by 2.4 percentage points to 21.3% due to lower raw material costs [2]. Market Outlook - The prices for key products such as lysine and threonine are currently at low levels, but demand is expected to recover as aquaculture penetration increases and consumer demand rebounds [3]. - The company is expanding its product line through acquisitions, which will enhance its high-value pharmaceutical amino acid offerings and support its international expansion strategy [3]. Profit Forecast and Valuation - The net profit forecast for 2025 has been adjusted down to RMB 3.54 billion, a 3% decrease from previous estimates, while maintaining projections of approximately RMB 3.6 billion and RMB 3.8 billion for 2026 and 2027 respectively [4]. - The expected earnings per share (EPS) for 2025 is RMB 1.26, with a projected price-to-earnings (P/E) ratio of 11x for 2025 [4][8].

Core Viewpoint - Meihua Biotechnology's stock has shown a mixed performance in recent trading, with a year-to-date increase of 16.35% and a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of October 30, Meihua Biotechnology's stock price rose by 2.01% to 11.18 CNY per share, with a trading volume of 296 million CNY and a turnover rate of 0.96%, resulting in a total market capitalization of 31.351 billion CNY [1] - The stock has experienced a 3.61% increase over the last five trading days and a 5.57% increase over the last 20 days, but a decline of 4.03% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Meihua Biotechnology reported a revenue of 18.215 billion CNY, a year-on-year decrease of 2.49%, while the net profit attributable to shareholders increased by 51.61% to 3.025 billion CNY [2] - The company has distributed a total of 12.047 billion CNY in dividends since its A-share listing, with 4.075 billion CNY distributed in the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 13.10% to 66,700, while the average circulating shares per person decreased by 13.09% to 42,058 shares [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 98.9229 million shares, an increase of 18.3366 million shares from the previous period [3] - New shareholders include Guotai CSI Livestock Breeding ETF and Southern S&P China A-share Large Cap Dividend Low Volatility 50 ETF, holding 44.5903 million shares and 32.0472 million shares, respectively [3]

证券代码：600873 证券简称：梅花生物 公告编号：2025-056 梅花生物科技集团股份有限公司 关于2025年前三季度经营数据公告 3、 按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 1,286,078.58 | | 国外 | 535,466.15 | | 合计 | 1,821,544.73 | 特此公告。 梅花生物科技集团股份有限公司董事会 2025 年 10 月 29 日 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条相关规定， 现将梅花生物科技集团股份有限公司 (以下简称"公司")2025 年前三季度经营 数据（未经审计）公告如下： 1、 按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 533,112.08 | | 饲料氨基酸（赖氨酸、苏氨酸、饲料级缬氨酸等） | 819,198.33 | | 医药氨基酸（谷氨酰胺、脯氨酸、异亮氨酸、鸟苷、腺苷等） | 46,909.91 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 290,884.73 ...

Core Viewpoint - The article discusses the recent approval of the arginine technology transformation project by Ningxia Yipin Biotechnology Co., Ltd., highlighting its significance in enhancing production capacity and efficiency in the amino acid manufacturing sector [2][3]. Project Overview - Project Name: Arginine Technology Transformation Project of Ningxia Yipin Biotechnology Co., Ltd. [3] - Construction Unit: Ningxia Yipin Biotechnology Co., Ltd. [3] - Nature of Construction: Technology transformation [3] - Industry Category: C1495 Food and Feed Additive Manufacturing [3] - Location: Yinchuan City, Ningxia Hui Autonomous Region [3] - Scale: The project aims to upgrade the existing L-arginine production line to produce feed-grade L-arginine, with an annual output of 10,000 tons post-transformation [3][4]. - Total Investment: 65.5157 million yuan, with 900,000 yuan allocated for environmental protection, accounting for 1.37% of the total investment [3]. - Construction Timeline: Expected to commence in June 2025 and complete trial production by September 2025, with a construction period of approximately 3 months [3]. Construction Details - The project will utilize the existing production facilities and fermentation equipment to enhance the production of arginine [4]. - New equipment to be acquired includes ceramic membranes, triple-effect crystallizers, fluidized beds, automatic packaging machines, and palletizers [4]. Product Capacity - Current Production Capacity: 4,000 tons of feed-grade L-arginine [5]. - Post-Transformation Capacity: 10,000 tons of feed-grade L-arginine, an increase of 6,000 tons [5]. - The new strain used in the project (Arg25-01) has an acid production rate approximately 2.5 times higher than the existing strain (Arg004-13), facilitating the increased capacity [5]. Existing Product Portfolio - The company is a leading player in the global bio-amino acid sector, with products including animal nutrition, food additives, and plant nutrition complex fertilizers [7]. - Key products include lysine, threonine, tryptophan, valine, and arginine, among other amino acid feed additives [7].

Investment Rating - The report maintains a "Buy" rating for the company [10] Core Insights - The company reported a revenue of 13.96 billion HKD for the first half of 2025, representing a year-on-year increase of 4.4%, primarily driven by growth in the animal nutrition segment [2][6] - The net profit attributable to shareholders reached 1.79 billion HKD, a significant year-on-year increase of 72.1%, mainly due to higher gross margins in the food additives and animal nutrition divisions [2][6] - The interim dividend declared is 0.365 HKD per share, which includes basic interim dividends, special interim dividends, and tax-exempt compensation [2][6] Summary by Sections Revenue and Profitability - The company achieved a revenue of 13.96 billion HKD, with the animal nutrition segment being the key contributor [2][6] - The net profit attributable to shareholders was 1.79 billion HKD, reflecting a substantial increase due to improved gross margins [2][6] Segment Performance - The food additives segment generated revenue of 6.47 billion HKD, with a gross margin of 15.8% [8] - The animal nutrition segment reported revenue of 5.41 billion HKD, with a gross margin of 28.2% [8] - The high-end amino acids segment achieved a revenue of 1.05 billion HKD, with a gross margin of 40.7% [8] Market Dynamics - The company is a leading player in the global monosodium glutamate industry, with expectations of increased demand as the industry recovers [8] - The company is actively expanding its international presence, with new production capacities coming online and a project in Kazakhstan underway [8]

Core Viewpoint - Meihua Biological has successfully completed its share repurchase plan, signaling strong financial health and stability in its operations, while also focusing on expanding its global presence in the amino acid industry [1][4]. Group 1: Share Repurchase and Financial Performance - The company repurchased 48.5471 million shares, accounting for 1.70% of its total share capital, at a price range of 9.10 to 10.97 yuan per share, totaling 492 million yuan [2][3]. - The repurchased shares will be canceled, reducing the total share capital from 2.853 billion shares to 2.804 billion shares, and increasing the shareholding ratio of major shareholders from 33.34% to 33.92% [2][3]. - In the first half of 2025, the company reported a net profit of 1.768 billion yuan, a year-on-year increase of 19.96%, despite a slight decline in revenue [6]. Group 2: Business Strategy and Market Position - Meihua Biological has focused on its core business of amino acids, enhancing its competitive edge through international expansion and refined operations [1][5]. - The company has maintained a stable profit distribution policy, with cumulative cash dividends exceeding 12 billion yuan since its restructuring in 2010, and a record dividend payout of 1.699 billion yuan for 2024 [3][4]. - The company has a diversified product matrix, leading in the production of lysine and threonine globally, and ranking second in MSG production [5]. Group 3: Research and Development - Meihua Biological has increased its R&D investment, with total R&D expenses reaching 897 million yuan over two and a half years, reflecting a commitment to maintaining its technological leadership in the industry [7]. - The company has accelerated its international strategy, completing a cross-border acquisition that enhances its product offerings and strengthens its global supply chain position [7].

Investment Rating - The report maintains a recommendation for SAF and epoxy resin, indicating a positive outlook for these materials in the chemical industry [1]. Core Insights - The new materials sector outperformed the broader market and the basic chemical sector, with the wind new materials index showing a weekly change of 2.53%, compared to 0.43% for the basic chemical index [8][9]. - The first global 6G chip has been launched, utilizing photonic technology to achieve a transmission speed of 100Gbps, which is expected to bridge the digital divide between urban and rural areas [4][11]. - The report highlights significant price increases for SAF in Europe (+11.01%) and China (+5.00%), as well as epoxy resin (+3.93%), while prices for threonine (-3.07%), lysine (-1.01%), and valine (-0.76%) saw declines [4][19]. Industry Updates - The report notes that the chemical industry is experiencing a recovery in prices due to easing trade tensions between China and the U.S., leading to a replenishment window in trade [9]. - The report emphasizes the importance of domestic production capabilities in new materials, particularly in light of ongoing trade tensions and the need for self-sufficiency [10]. - The report suggests that the new materials sector, particularly those with high growth potential and strong technological barriers, is poised for significant investment opportunities [14]. Trading Data - The Huachuang Chemical Industry Index stands at 71.65, reflecting a week-on-week increase of 0.59% but a year-on-year decrease of 21.87% [15][20]. - The industry price percentile is at 17.84% over the past decade, indicating a slight increase, while the industry inventory percentile is at 80.18%, suggesting a relatively high level of inventory [15]. Subsector Tracking - In the new energy materials sector, the report mentions the pricing of the SAIC MG4 semi-solid-state battery version at 99,800 yuan [27]. - The report also highlights the expected growth in the global robotics market, projected to exceed $400 billion by 2029, with China capturing nearly half of that market share [11].